NASDAQ / LIVE COMPANY INTELLIGENCE

Sutro Biopharma, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERSTRO
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / STRO COVERAGE

What’s moving Sutro Biopharma, Inc. now

Current reporting with the operating signal separated from the noise.

01
Sutro Biopharma, Inc. (STRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Sutro Biopharma, Inc. (STRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

The story matters when it changes Sutro Biopharma, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Sutro Biopharma, Inc. (STRO) Discusses Strategic Reset and Progress in Next-Generation ADC Pipeline and Platform Innovation Transcript

Sutro Biopharma, Inc. (STRO) Discusses Strategic Reset and Progress in Next-Generation ADC Pipeline and Platform Innovation Transcript

The story matters when it changes Sutro Biopharma, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Beats Revenue Estimates

Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Beats Revenue Estimates

Investors are testing whether Sutro Biopharma, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
04
Sutro Biopharma, Inc. Advances ADC Pipeline Focus with Promising Preclinical Results and Strategic Reprioritization

Sutro Biopharma, Inc. Advances ADC Pipeline Focus with Promising Preclinical Results and Strategic Reprioritization

The story matters when it changes Sutro Biopharma, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
All You Need to Know About Sutro Biopharma, Inc. (STRO) Rating Upgrade to Buy

All You Need to Know About Sutro Biopharma, Inc. (STRO) Rating Upgrade to Buy

The story matters when it changes Sutro Biopharma, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest STRO filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-14 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-06 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-03-23 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-06-08 · Period 2026-06-05SEC ↗8-KMaterial company eventFiled 2026-05-14 · Period 2026-05-14SEC ↗8-KMaterial company eventFiled 2026-03-23 · Period 2026-03-23SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-22 · Period 2026-06-05SEC ↗SCHEDULE 13GOfficial SEC filingFiled 2026-07-30SEC ↗
EARNINGS / QUARTERLY TRACKER

Sutro Biopharma, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.